This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Daniel J. McCarty, Jr, MD

JAMA. 1993;270(2):260-262.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The sporadic reports of connective tissue disorders in women who have had breast augmentation mammaplasties using silicone implants led the Food and Drug Administration (FDA) to withdraw approval for the procedure, except for breast reconstruction after cancer surgery.¹ Even in this situation, implants are now available only if the patient agrees to become a subject in a clinical trial. Understandably, the FDA decision has elicited reactions ranging from dismay to panic in the more than 2 million American women who have had silicone implants. Plastic surgeons and lawyers have been contacted in large numbers. Polymeric silicone substances have been and are being used for penile implants and for arthroplasty of the wrist and metacarpophalangeal and metatarsophalangeal joints. The safety of these devices has also been questioned, but the FDA has not yet withdrawn them from the marketplace.

Reports of single cases and small series of patients who developed rheumatic . . . [Full Text PDF of this Article]

Author Affiliations
Medical College of Wisconsin, Milwaukee

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?